Pharmacological evaluation of phage-antibiotic synergism against clinical isolates of multi-drug resistant Staphylococcus aureus in a burn-induced infection mouse model
Abstract
Multidrug resistant Staphylococcus aureus (MDRSA) is a superbug that shows enormous resistance to many antibiotics. Identified by the World Health Organization as one of the high priority pathogens, there is an urgent need to develop new antibiotic strategies against MDRSA. One such approach is the use of bacteriophages as antimicrobial agents. When bacteriophages are used in combination with antibiotics, phage-antibiotic synergism (PAS) effectively inhibits bacteria. The current study evaluated various phage-antibiotic combinations to determine the optimal PAS activity against 10 clinical isolates of MDRSA, both in vitro and in a burn-induced wound infection mouse model (n = 3/ group). A novel phage, SDAH-01, was isolated locally and characterized. After establishing in vitro antibacterial activity, a burn-induced skin infection mouse model was used to evaluate PAS activity. Wound contraction, bacterial load, and histopathological changes were observed over the duration of treatment. Inflammatory markers (IL-6, TNF-α, VEGF) were evaluated using immunohistochemical methods. Optimal combinations of phages with amoxicillin, azithromycin, and ciprofloxacin significantly inhibited bacterial growth and promoted wound healing as compared to monotherapies. By Day 14, phage-amoxicillin resulted in a 6-log reduction in bacterial load, showing the maximum activity. Similarly, phage-azithromycin and phage-ciprofloxacin combinations showed significant reductions in comparison to…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.